Segment Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($) product segment	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Segment Information
Number of operating segments | segment	1
Number of commercial products | product	5
Net revenues, cost of product sales and gross profit
Net product sales	$ 1,460,570	$ 1,279,533	$ 1,106,944
Cost of product sales	69,036	125,883	131,127
Gross profit	1,391,534	1,153,650	975,817
Remodulin
Net revenues, cost of product sales and gross profit
Net product sales	572,795	553,728	491,179
Cost of product sales	12,373	47,327	59,314
Gross profit	560,422	506,401	431,865
Tyvaso
Net revenues, cost of product sales and gross profit
Net product sales	470,069	463,067	438,793
Cost of product sales	23,925	57,442	60,831
Gross profit	446,144	405,625	377,962
Adcirca
Net revenues, cost of product sales and gross profit
Net product sales	278,829	221,471	176,972
Cost of product sales	16,504	13,495	10,982
Gross profit	262,325	207,976	$ 165,990
Orenitram
Net revenues, cost of product sales and gross profit
Net product sales	118,434	41,267
Cost of product sales	12,569	7,619
Gross profit	105,865	$ 33,648
Unituxin
Net revenues, cost of product sales and gross profit
Net product sales	20,443
Cost of product sales	3,665
Gross profit	$ 16,778